Menú

Filtros

  • Resultados obtenidos en

OSOM® Flu SARS-CoV-2 Combo Test

OSOM® Flu SARS-CoV-2 Combo Test

OSOM® Flu SARS-CoV-2 Combo Test

Are you prepared for respiratory infection season?

Respiratory infection season generally extends from late fall through early spring, leading to a sharp increase in illnesses caused by a range of pathogens, most notably COVID-19* and influenza. The simultaneous circulation of these viruses poses substantial challenges for healthcare systems, underscoring the need for proactive strategies to reduce their impact.

Implementing a rapid COVID-19* and Flu Combo Antigen Test can help optimize timely and accurate diagnoses, enabling effective management and mitigation of these challenges.

The Challenges when COVID-19* and Flu are Cocirculating.¹

  • Due to the similarities in symptoms, it is difficult to distinguish between symptoms alone.
  • It is difficult to rely on empirical treatment alone, due to the difference in recommended antivirals.
  • Coinfection is possible, which can lead to an increased mortality rate and healthcare expenditures.

Answering the need to clinically differentiate between COVID-19* and Flu.

From only one sample, the OSOM® Flu SARS-CoV-2 Combo Test simultaneously detects and differentiates between COVID-19, Flu A, and Flu B in only 10 minutes, allowing healthcare providers to make more informed decisions when treating patients who are symptomatic for common viral infections.

Resources:
Sales Sheet | Instructions for Use (IFU)

OSOM® Flu SARS-CoV-2 Combo Test
Reference:
¹ Garg, I. COVID-19 and Influenza Coinfection Outcomes among Hospitalized Patients in the US. Vaccines 2022, 10, 2159.

*This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens; and The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Continuar comprando Añadir
Henry Schein Henry Schein